Want to join the conversation?
Medical device maker $BSX received FDA approval for SYNERGY Bioabsorbable Polymer Drug-Eluting Stent (BP-DES) for the treatment of CAD. $BSX to commence commercialization of the first & only BP-DES in the US immediately. Four-year EVOLVE trial of BP-DES data showed a continued 0% stent thrombosis rate & a low 1.1% rate of lesion revascularization.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.